Vapotherm, Inc. (NYSE:VAPO) is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, VAPO is expected to report 3Q20 loss of $ 0.56 per share from revenue of $ 24.13 million.
For the full year, analysts anticipate top line of $ 97.26 million, while looking forward to loss of $ 2.1 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 24.00 million ~ $ 28.00 million
Full Year 2020 topline are forecasted in a range of$ 52.90 million ~ $ 54.50 million
Click Here For More Historical Outlooks Of Vapotherm, Inc.
Previous Quarter Performance
Vapotherm, Inc. reported loss for the second quarter of $ 0.35 per share, from the revenue of $ 35.15 million. The quarterly revenues increased 193.16 percent compared with the same quarter last year. According to street consensus, VAPO was expected to report 2Q20 loss of $ 0.39 per share from revenue of $ 33.47 million. The bottom line results beat street analysts by $ 0.04 or 10.26 percent, at the same time, top line results outshined analysts by $ 1.68 million or 5.02 percent.
Stock Performance
Shares of Vapotherm, Inc. traded up $ 2.99 or 10.37 percent on Tuesday, reaching $ 31.83 with volume of 475.20 thousand shares. Vapotherm, Inc. has traded high as $ 32.00 and has cracked $ 29.10 on the downward trend
According to the previous trading day, closing price of $ 31.83, representing a 320.41 % increase from the 52 week low of $ 6.86 and a 47 % decrease over the 52 week high of $ 54.42.
The company has a market capital of $ 813.90 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Vapotherm, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.vapotherm.com
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces.
